Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | SCD | O00767 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14154504 | 0.90 | SCD (0.42) | TNKSTNKS2IDO1AVPR1AS1PR5 | |
| SCHEMBL7821093 | 0.85 | KCNH2 (0.41) | SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL21029007 | 0.83 | TNKS (0.43) | TNKSTNKS2IDO1AVPR1AS1PR5 | |
| SCHEMBL30079574 | 0.83 | TNKS (0.43) | TNKSTNKS2IDO1AVPR1AS1PR5 | |
| SCHEMBL25681344 | 0.83 | TNKS (0.45) | TNKSTNKS2IDO1AVPR1AS1PR5 | |
| SCHEMBL22514004 | 0.82 | SCD (0.37) | TNKSTNKS2IDO1AVPR1ASCD | |
| SCHEMBL9060153 | 0.82 | ALDH1A1 (0.40) | TNKSTNKS2IDO1AVPR1ASIGMAR1 | |
| SCHEMBL8014729 | 0.82 | S1PR5 (0.44) | TNKSTNKS2IDO1AVPR1AS1PR5 | |
| SCHEMBL14112073 | 0.82 | CYP2D6 (0.46) | TNKSTNKS2IDO1AVPR1AS1PR5 | |
| SCHEMBL29597292 | 0.82 | GRIN2D (0.46) | TNKSTNKS2IDO1AVPR1AS1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-20220000856-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | JANSSEN PHARMACEUTICALS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11071729-B2 | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones | ADDEX PHARMACEUTICALS S.A. (CH) | 2021-07-27 | — | — | US | disclosed |
| WO-2021115286-A1 | SIX-MEMBERED AND FIVE-MEMBERED AROMATIC RING DERIVATIVE CONTAINING NITROGEN HETEROATOMS WHICH CAN BE USED AS SHP2 INHIBITOR | 成都倍特药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-20200038391-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | JANSSEN PHARMACEUTICALS INC (US) | 2020-02-06 | — | — | US | disclosed |
| EP-2927214-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-5952325-A | Tricyclic spiro compounds process for their preparation and their use of 5HT1D receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-09-14 | — | — | US | disclosed |
| EP-0854717-A1 | USE OF 5HT 1B? RECEPTOR ANTAGONIST FOR THE TREATMENT OF VASCULAR DISEASE | SMITHKLINE BEECHAM PLC (GB) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997010824-A1 | USE OF 5HT1B RECEPTOR ANTAGONIST FOR THE TREATMENT OF VASCULAR DISEASE | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-03-27 | — | — | WO | disclosed |
| WO-1996011934-A1 | TRICYCLIC SPIRO COMPOUNDS PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-25 | — | — | WO | disclosed |
| EP-0702681-A1 | SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ ANTAGONISTS | MERCK & CO. INC. (US) | 1996-03-27 | — | — | EP | disclosed |
| WO-1994029309-A1 | SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| US-4593033-A | Cardiovascular disorders | MERCK & CO., INC. (US) | 1986-06-03 | — | — | US | disclosed |
| US-4548941-A | 1,5-Methano-1H-4-benzazonine dicarboxylates, process for preparing and use as calcium blockers | MERCK & CO., INC. (US) | 1985-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | TNKS 1283/4885TNKS2 2191/4885IDO1 730/4885 |
| US-11071729-B2 | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones | GRM2, GRM1, GRIN2C | TNKS 3940/4885TNKS2 3346/4885IDO1 902/4885 |
| US-20220000856-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | GRM2, GRM1, GRIN2C | TNKS 3898/4885TNKS2 3310/4885IDO1 788/4885 |
| US-20200038391-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | GRM2, GRM1, GRIN2C | TNKS 3898/4885TNKS2 3310/4885IDO1 788/4885 |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | TNKS 3017/4885TNKS2 2437/4885IDO1 1145/4885 |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | TNKS 2344/4885TNKS2 2493/4885IDO1 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.